Chemokine-dependent B cell–T cell interactions in chronic lymphocytic leukemia and multiple myeloma – targets for therapeutic intervention?

Bibliography

• Mellado M, Vila-Coro AJ, Martinez C, Rodriguez-Frade JM. Receptor dimerization: a key step in chemokine signaling. Cell Mol Biol (Noisy-le-grand) 2001;47:575-82
   PubMed Web of Science ®Google Scholar
• Thelen M. Dancing to the tune of chemokines. Nat Immunol 2001;2:129-34
   PubMed Web of Science ®Google Scholar
• Bennett LD, Fox JM, Signoret N. Mechanisms regulating chemokine receptor activity. Immunology 2011;134:246-56
   PubMed Web of Science ®Google Scholar
• Sharma M. Chemokines and their receptors: orchestrating a fine balance between health and disease. Crit Rev Biotechnol 2010;30:1–22
   Web of Science ®Google Scholar
• Kulbe H, Levinson NR, Balkwill F, Wilson JL. The chemokine network in cancer–much more than directing cell movement. Int J Dev Biol 2004;48:489-96
   PubMed Web of Science ®Google Scholar
• Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009;114:3367-75
   PubMed Web of Science ®Google Scholar
• Baekkevold ES, Yamanaka T, Palframan RT, The CCR7 ligand elc (CCL19) is transcytosed in high endothelial venules and mediates T cell recruitment. J Exp Med 2001;193:1105-12
   PubMed Web of Science ®Google Scholar
• Ebisuno Y, Tanaka T, Kanemitsu N, Cutting edge: the B cell chemokine CXC chemokine ligand 13/B lymphocyte chemoattractant is expressed in the high endothelial venules of lymph nodes and Peyer's patches and affects B cell trafficking across high endothelial venules. J Immunol 2003;171:1642-6
   PubMed Web of Science ®Google Scholar
• Kanemitsu N, Ebisuno Y, Tanaka T, CXCL13 is an arrest chemokine for B cells in high endothelial venules. Blood 2005;106:2613-18
   PubMed Web of Science ®Google Scholar
• Okada T, Ngo VN, Ekland EH, Chemokine requirements for B cell entry to lymph nodes and Peyer's patches. J Exp Med 2002;196:65-75
   PubMed Web of Science ®Google Scholar
• Gunn MD, Kyuwa S, Tam C, Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med 1999;189:451-60
   PubMed Web of Science ®Google Scholar
• Nakano H, Mori S, Yonekawa H, A novel mutant gene involved in T-lymphocyte-specific homing into peripheral lymphoid organs on mouse chromosome 4. Blood 1998;91:2886-95
   PubMed Web of Science ®Google Scholar
• Cyster JG. Chemokines and cell migration in secondary lymphoid organs. Science 1999;286:2098-102
   PubMed Web of Science ®Google Scholar
• Cyster JG, Ansel KM, Reif K, Follicular stromal cells and lymphocyte homing to follicles. Immunol Rev 2000;176:181-93
   PubMed Web of Science ®Google Scholar
• Ohl L, Henning G, Krautwald S, Cooperating mechanisms of CXCR5 and CCR7 in development and organization of secondary lymphoid organs. J Exp Med 2003;197:1199-204
   PubMed Web of Science ®Google Scholar
• Forster R, Schubel A, Breitfeld D, CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999;99:23-33
   PubMed Web of Science ®Google Scholar
• Liu YJ, Arpin C. Germinal center development. Immunol Rev 1997;156:111-26
   PubMed Web of Science ®Google Scholar
• Reif K, Ekland EH, Ohl L, Balanced responsiveness to chemoattractants from adjacent zones determines B-cell position. Nature 2002;416:94-9
   PubMed Web of Science ®Google Scholar
• Bystry RS, Aluvihare V, Welch KA, B cells and professional APCs recruit regulatory T cells via CCL4. Nat Immunol 2001;2:1126-32
   PubMed Web of Science ®Google Scholar
• Schaniel C, Pardali E, Sallusto F, Activated murine B lymphocytes and dendritic cells produce a novel CC chemokine which acts selectively on activated T cells. J Exp Med 1998;188:451-63
   PubMed Web of Science ®Google Scholar
• Krzysiek R, Lefevre EA, Zou W, Antigen receptor engagement selectively induces macrophage inflammatory protein-1alpha (MIP-1 alpha) and MIP-1beta chemokine production in human B cells. J Immunol 1999;162:4455-63
   PubMed Web of Science ®Google Scholar
• Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011;29:621-63
   PubMed Web of Science ®Google Scholar
• Deenick EK, Ma CS, Brink R, Tangye SG. Regulation of T follicular helper cell formation and function by antigen presenting cells. Curr Opin Immunol 2011;23:111-18
   PubMed Web of Science ®Google Scholar
• Ansel KM, McHeyzer-Williams LJ, Ngo VN, In vivo-activated CD4 T cells upregulate CXC chemokine receptor 5 and reprogram their response to lymphoid chemokines. J Exp Med 1999;190:1123-34
   PubMed Web of Science ®Google Scholar
• Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 1998;8:363-72
   PubMed Web of Science ®Google Scholar
• Pelletier N, McHeyzer-Williams LJ, Wong KA, Plasma cells negatively regulate the follicular helper T cell program. Nat Immunol 2010;11:1110-18
   Google Scholar
• Schaerli P, Willimann K, Lang AB, CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med 2000;192:1553-62
   PubMed Web of Science ®Google Scholar
• Allen CD, Ansel KM, Low C, Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat Immunol 2004;5:943-52
   PubMed Web of Science ®Google Scholar
• MacLennan IC. Germinal centers. Annu Rev Immunol 1994;12:117-39
   PubMed Web of Science ®Google Scholar
• Okada T, Miller MJ, Parker I, Antigen-engaged B cells undergo chemotaxis toward the T zone and form motile conjugates with helper T cells. PLoS Biol 2005;3:e150
   PubMed Web of Science ®Google Scholar
• Hargreaves DC, Hyman PL, Lu TT, A coordinated change in chemokine responsiveness guides plasma cell movements. J Exp Med 2001;194:45-56
   PubMed Web of Science ®Google Scholar
• Nie Y, Waite J, Brewer F, The role of CXCR4 in maintaining peripheral B cell compartments and humoral immunity. J Exp Med 2004;200:1145-56
   PubMed Web of Science ®Google Scholar
• Hauser AE, Debes GF, Arce S, Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response. J Immunol 2002;169:1277-82
   PubMed Web of Science ®Google Scholar
• Odendahl M, Mei H, Hoyer BF, Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 2005;105:1614-21
   PubMed Web of Science ®Google Scholar
• Muehlinghaus G, Cigliano L, Huehn S, Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood 2005;105:3965-71
   PubMed Web of Science ®Google Scholar
• Balabanian K, Lagane B, Infantino S, The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 2005;280:35760-6
   PubMed Web of Science ®Google Scholar
• Burns JM, Summers BC, Wang Y, A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006;203:2201-13
   PubMed Web of Science ®Google Scholar
• Hartmann TN, Grabovsky V, Pasvolsky R, A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells. J Leukoc Biol 2008;84:1130-40
   PubMed Web of Science ®Google Scholar
• Rot A. Chemokine patterning by glycosaminoglycans and interceptors. Front Biosci 2010;15:645-60
   Web of Science ®Google Scholar
• Levoye A, Balabanian K, Baleux F, CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 2009;113:6085-93
   PubMed Web of Science ®Google Scholar
• Minges Wols HA, Underhill GH, Kansas GS, Witte PL. The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity. J Immunol 2002;169:4213-21
   PubMed Web of Science ®Google Scholar
• Tokoyoda K, Zehentmeier S, Hegazy AN, Professional memory CD4+ T lymphocytes preferentially reside and rest in the bone marrow. Immunity 2009;30:721-30
   PubMed Web of Science ®Google Scholar
• Di Rosa F, Santoni A. Memory T-cell competition for bone marrow seeding. Immunology 2003;108:296-304
   PubMed Web of Science ®Google Scholar
• Becker TC, Coley SM, Wherry EJ, Ahmed R. Bone marrow is a preferred site for homeostatic proliferation of memory CD8 T cells. J Immunol 2005;174:1269-73
   PubMed Web of Science ®Google Scholar
• Parretta E, Cassese G, Barba P, CD8 cell division maintaining cytotoxic memory occurs predominantly in the bone marrow. J Immunol 2005;174:7654-64
   PubMed Web of Science ®Google Scholar
• Herndler-Brandstetter D, Landgraf K, Jenewein B, Human bone marrow hosts polyfunctional memory CD4+ and CD8+ T cells with close contact to IL-15-producing cells. J Immunol 2011;186:6965-71
   PubMed Web of Science ®Google Scholar
• Feuerer M, Beckhove P, Mahnke Y, Bone marrow microenvironment facilitating dendritic cell: CD4 T cell interactions and maintenance of CD4 memory. Int J Oncol 2004;25:867-76
   PubMed Web of Science ®Google Scholar
• Reichardt P, Dornbach B, Rong S, Naive B cells generate regulatory T cells in the presence of a mature immunologic synapse. Blood 2007;110:1519-29
   Web of Science ®Google Scholar
• Molon B, Gri G, Bettella M, T cell costimulation by chemokine receptors. Nat Immunol 2005;6:465-71
   PubMed Web of Science ®Google Scholar
• Viola A, Contento RL, Molon B. T cells and their partners: the chemokine dating agency. Trends Immunol 2006;27:421-7
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F. Role of the microenvironment in chronic lymphocytic leukaemia. Br J Haematol 2003;123:380-8
   PubMed Web of Science ®Google Scholar
• Foucar K, Friedman K, Llewellyn A, Prenatal diagnosis of transient myeloproliferative disorder via percutaneous umbilical blood sampling. Report of two cases in fetuses affected by Down's syndrome. Am J Clin Pathol 1992;97:584-90
   PubMed Web of Science ®Google Scholar
• Ghia P, Strola G, Granziero L, Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur J Immunol 2002;32:1403-13
   PubMed Web of Science ®Google Scholar
• Mellstedt H, Choudhury A. T and B cells in B-chronic lymphocytic leukaemia: faust, Mephistopheles and the pact with the Devil. Cancer Immunol Immunother 2006;55:210-20
   PubMed Web of Science ®Google Scholar
• Totterman TH, Carlsson M, Simonsson B, T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease. Blood 1989;74:786-92
   PubMed Web of Science ®Google Scholar
• Tinhofer I, Weiss L, Gassner F, Difference in the relative distribution of CD4+ T-cell subsets in B-CLL with mutated and unmutated immunoglobulin (Ig) VH genes: implication for the course of disease. J Immunother 2009;32:302-9
   PubMed Web of Science ®Google Scholar
• Pinon Hofbauer JP, Heyder C, Denk U, Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL. Leukemia 2011;25:1452-8
   PubMed Web of Science ®Google Scholar
• Piper KP, Karanth M, McLarnon A, Chronic lymphocytic leukaemia cells drive the global CD4+ T cell repertoire towards a regulatory phenotype and leads to the accumulation of CD4+ forkhead box P3+ T cells. Clin Exp Immunol 2011;166:154-63
   PubMed Web of Science ®Google Scholar
• Patten PE, Buggins AG, Richards J, CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 2008;111:5173-81
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Johnson AJ, Lee AM, Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008;118:2427-37
   PubMed Web of Science ®Google Scholar
• Durig J, Ebeling P, Grabellus F, A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease. Cancer Res 2007;67:8653-61
   PubMed Web of Science ®Google Scholar
• Bagnara D, Kaufman MS, Calissano C, A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood 2011;117:5463-72
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Gonzalez M, Gascon A, Lymphoid subsets and prognostic factors in multiple myeloma. Cooperative Group for the Study of Monoclonal Gammopathies. Br J Haematol 1992;80:305-9
   PubMed Web of Science ®Google Scholar
• Kay NE, Leong T, Bone N, T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93. Br J Haematol 1998;100:459-63
   PubMed Web of Science ®Google Scholar
• Li Y, Chen S, Yang L, Change in expression pattern of TCR-CD3 complex in patients with multiple myeloma. Hematology (Am Soc Hematol Educ Program) 2011;16:143-50
   Google Scholar
• Perez-Andres M, Almeida J, Martin-Ayuso M, Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vbeta repertoire. Cancer 2006;106:1296-305
   PubMed Web of Science ®Google Scholar
• Koike M, Sekigawa I, Okada M, Relationship between CD4+/CD8+ T cell ratio and T cell activation in multiple myeloma: reference to IL-16. Leuk Res 2002;26:705-11
   PubMed Web of Science ®Google Scholar
• Massaia M, Bianchi A, Attisano C, Detection of hyperreactive T cells in multiple myeloma by multivalent cross-linking of the CD3/TCR complex. Blood 1991;78:1770-80
   PubMed Web of Science ®Google Scholar
• Dianzani U, Pileri A, Boccadoro M, Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. Blood 1988;72:1064-8
   PubMed Web of Science ®Google Scholar
• Tinhofer I, Marschitz I, Henn T, Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood 2000;95:610-18
   PubMed Web of Science ®Google Scholar
• Hilbert DM, Shen MY, Rapp UR, Rudikoff S. T cells induce terminal differentiation of transformed B cells to mature plasma cell tumors. Proc Natl Acad Sci USA 1995;92:649-53
   PubMed Web of Science ®Google Scholar
• Wong S, Fulcher D. Chemokine receptor expression in B-cell lymphoproliferative disorders. Leuk Lymphoma 2004;45:2491-6
   PubMed Web of Science ®Google Scholar
• Till KJ, Lin K, Zuzel M, Cawley JC. The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood 2002;99:2977-84
   PubMed Web of Science ®Google Scholar
• Lopez-Giral S, Quintana NE, Cabrerizo M, Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. J Leukoc Biol 2004;76:462-71
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Bone ND, Stenson MJ, Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. Mayo Clin Proc 2004;79:318-25
   PubMed Web of Science ®Google Scholar
• Richardson SJ, Matthews C, Catherwood MA, ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006;107:3584-92
   PubMed Web of Science ®Google Scholar
• Redondo-Munoz J, Jose TM, Garcia-Marco JA, Garcia-Pardo A. Matrix metalloproteinase-9 is up-regulated by CCL21/CCR7 interaction via extracellular signal-regulated kinase-1/2 signaling and is involved in CCL21-driven B-cell chronic lymphocytic leukemia cell invasion and migration. Blood 2008;111:383-6
   PubMed Web of Science ®Google Scholar
• Chunsong H, Yuling H, Li W, CXC chemokine ligand 13 and CC chemokine ligand 19 cooperatively render resistance to apoptosis in B cell lineage acute and chronic lymphocytic leukemia CD23+CD5+ B cells. J Immunol 2006;177:6713-22
   PubMed Web of Science ®Google Scholar
• Burkle A, Niedermeier M, Schmitt-Graff A, Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood 2007;110:3316-25
   PubMed Web of Science ®Google Scholar
• Burger JA, Quiroga MP, Hartmann E, High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009;113:3050-8
   PubMed Web of Science ®Google Scholar
• Sivina M, Hartmann E, Kipps TJ, CCL3 (MIP-1alpha) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood 2011;117:1662-9
   PubMed Web of Science ®Google Scholar
• Zucchetto A, Benedetti D, Tripodo C, CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res 2009;69:4001-9
   PubMed Web of Science ®Google Scholar
• Trentin L, Miorin M, Facco M, Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity. Br J Haematol 2007;138:594-602
   PubMed Web of Science ®Google Scholar
• Alsayed Y, Ngo H, Runnels J, Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 2007;109:2708-17
   PubMed Web of Science ®Google Scholar
• Choi SJ, Cruz JC, Craig F, Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000;96:671-5
   PubMed Web of Science ®Google Scholar
• Magrangeas F, Nasser V, Avet-Loiseau H, Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood 2003;101:4998-5006
   PubMed Web of Science ®Google Scholar
• Sanz-Rodriguez F, Hidalgo A, Teixido J. Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood 2001;97:346-51
   PubMed Web of Science ®Google Scholar
• Parmo-Cabanas M, Bartolome RA, Wright N, Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion. Exp Cell Res 2004;294:571-80
   PubMed Web of Science ®Google Scholar
• Vanderkerken K, Vande Broek I, Eizirik DL, Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T multiple myeloma cells. Clin Exp Metastasis 2002;19:87-90
   PubMed Web of Science ®Google Scholar
• Johrer K, Janke K, Krugmann J, Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)-alpha via TNF receptor 2 and autocrine up-regulation of MCP-1. Clin Cancer Res 2004;10:1901-10
   PubMed Web of Science ®Google Scholar
• Vande Broek I, Asosingh K, Vanderkerken K, Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3. Br J Cancer 2003;88:855-62
   PubMed Web of Science ®Google Scholar
• Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood 2000;95:627-32
   PubMed Web of Science ®Google Scholar
• Ocana E, Delgado-Perez L, Campos-Caro A, The prognostic role of CXCR3 expression by chronic lymphocytic leukemia B cells. Haematologica 2007;92:349-56
   PubMed Web of Science ®Google Scholar
• Giuliani N, Bonomini S, Romagnani P, CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. Haematologica 2006;91:1489-97
   PubMed Web of Science ®Google Scholar
• Pellegrino A, Antonaci F, Russo F, CXCR3-binding chemokines in multiple myeloma. Cancer Lett 2004;207:221-7
   PubMed Web of Science ®Google Scholar
• Foa R, Giovarelli M, Jemma C, Interleukin 2 (IL 2) and interferon-gamma production by T lymphocytes from patients with B-chronic lymphocytic leukemia: evidence that normally released IL 2 is absorbed by the neoplastic B cell population. Blood 1985;66:614-19
   PubMed Web of Science ®Google Scholar
• Gallego A, Vargas JA, Castejon R, Production of intracellular IL-2, TNF-alpha, and IFN-gamma by T cells in B-CLL. Cytometry B Clin Cytom 2003;56:23-9
   PubMedGoogle Scholar
• Podhorecka M, Dmoszynska A, Rolinski J. Intracellular IFN-gamma expression by CD3+/CD8+ cell subset in B-CLL patients correlates with stage of the disease. Eur J Haematol 2004;73:29-35
   PubMed Web of Science ®Google Scholar
• Kiaii S, Choudhury A, Mozaffari F, Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia: long-term effects of fludarabine and alemtuzumab treatment. Leuk Lymphoma 2006;47:1229-38
   PubMed Web of Science ®Google Scholar
• Buschle M, Campana D, Carding SR, Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med 1993;177:213-18
   PubMed Web of Science ®Google Scholar
• Wilkinson PC, Islam LN. Recombinant IL-4 and IFN-gamma activate locomotor capacity in human B lymphocytes. Immunology 1989;67:237-43
   PubMed Web of Science ®Google Scholar
• Rojas R, Roman J, Torres A, Inhibition of apoptotic cell death in B-CLL by interferon gamma correlates with clinical stage. Leukemia 1996;10:1782-8
   PubMed Web of Science ®Google Scholar
• Zaki M, Douglas R, Patten N, Disruption of the IFN-gamma cytokine network in chronic lymphocytic leukemia contributes to resistance of leukemic B cells to apoptosis. Leuk Res 2000;24:611-21
   PubMed Web of Science ®Google Scholar
• Jenh CH, Cox MA, Hipkin W, Human B cell-attracting chemokine 1 (BCA-1; CXCL13) is an agonist for the human CXCR3 receptor. Cytokine 2001;15:113-21
   PubMed Web of Science ®Google Scholar
• Calissano C, Damle RN, Marsilio S, Intra-clonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/quiescent cells. Mol Med 2011; published online 23 September 2011; doi:; 10.2119/molmed.2011.00360
   PubMed Web of Science ®Google Scholar
• Vlad A, Deglesne PA, Letestu R, Down-regulation of CXCR4 and CD62L in chronic lymphocytic leukemia cells is triggered by B-cell receptor ligation and associated with progressive disease. Cancer Res 2009;69:6387-95
   PubMed Web of Science ®Google Scholar
• Quiroga MP, Burger JA. BCR-mediated decrease of CXCR4 and CD62L in CLL. Cancer Res 2010;70:5194
   PubMed Web of Science ®Google Scholar
• Romagnani P, Annunziato F, Lasagni L, Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest 2001;107:53-63
   PubMed Web of Science ®Google Scholar
• Haabeth OA, Lorvik KB, Hammarstrom C, Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun 2011;2:240
   PubMed Web of Science ®Google Scholar
• Luster AD, Leder P. IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med 1993;178:1057-65
   PubMed Web of Science ®Google Scholar
• Li G, Tian L, Hou JM, Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with Cisplatin in solid tumors. Clin Cancer Res 2005;11:4217-24
   PubMed Web of Science ®Google Scholar
• Teichmann M, Meyer B, Beck A, Niedobitek G. Expression of the interferon-inducible chemokine IP-10 (CXCL10), a chemokine with proposed anti-neoplastic functions, in Hodgkin lymphoma and nasopharyngeal carcinoma. J Pathol 2005;206:68-75
   PubMed Web of Science ®Google Scholar
• Mohle R, Failenschmid C, Bautz F, Kanz L. Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1). Leukemia 1999;13:1954-9
   PubMed Web of Science ®Google Scholar
• Rehm A, Mensen A, Schradi K, Cooperative function of CCR7 and lymphotoxin in the formation of a lymphoma-permissive niche within murine secondary lymphoid organs. Blood 2011;118:1020-33
   PubMed Web of Science ®Google Scholar
• Hasegawa H, Nomura T, Kohno M, Increased chemokine receptor CCR7/EBI1 expression enhances the infiltration of lymphoid organs by adult T-cell leukemia cells. Blood 2000;95:30-8
   PubMed Web of Science ®Google Scholar
• Hopken UE, Foss HD, Meyer D, Up-regulation of the chemokine receptor CCR7 in classical but not in lymphocyte-predominant Hodgkin disease correlates with distinct dissemination of neoplastic cells in lymphoid organs. Blood 2002;99:1109-16
   PubMed Web of Science ®Google Scholar
• Muller A, Homey B, Soto H, Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-6
   PubMed Web of Science ®Google Scholar
• Ding Y, Shimada Y, Maeda M, Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin Cancer Res 2003;9:3406-12
   PubMed Web of Science ®Google Scholar
• Alfonso-Perez M, Lopez-Giral S, Quintana NE, Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia. J Leukoc Biol 2006;79:1157-65
   PubMed Web of Science ®Google Scholar
• Wiley HE, Gonzalez EB, Maki W, Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst 2001;93:1638-43
   PubMed Web of Science ®Google Scholar
• Panjideh H, Koch M, Oden F, CXCR5-directed Immunotherapy of B cell Non-Hodgkin lymphoma and autoimmune disease. Int Immmunol Suppl 2010;22:v23
   Google Scholar
• Wijtmans M, Verzijl D, Leurs R, Towards small-molecule CXCR3 ligands with clinical potential. ChemMedChem 2008;3:861-72
   PubMed Web of Science ®Google Scholar
• Cambien B, Karimdjee BF, Richard-Fiardo P, Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. Br J Cancer 2009;100:1755-64
   PubMed Web of Science ®Google Scholar
• Walser TC, Rifat S, Ma X, Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res 2006;66:7701-7
   PubMed Web of Science ®Google Scholar
• Horuk R. Chemokine receptor antagonists: overcoming developmental hurdles. Nat Rev Drug Discov 2009;8:23-33
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb. A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis. ClinicalTrials.gov NCT00295282. Available from: http://clinicaltrials.gov/ct2/show/NCT00295282?term=NCT00295282&rank=1
   Google Scholar
• Bristol-Myers Squibb. A Study of MDX-1100 in Subjects With Active Ulcerative Colitis. ClinicalTrials.gov NCT00656890. Available from: http://clinicaltrials.gov/ct2/show/NCT00656890?term=NCT00656890&rank=1
   Google Scholar
• Bertolini F, Dell'Agnola C, Mancuso P, CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res 2002;62:3106-12
   PubMed Web of Science ®Google Scholar
• Devine SM, Flomenberg N, Vesole DH, Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004;22:1095-102
   PubMed Web of Science ®Google Scholar
• Flomenberg N, Comenzo RL, Badel K, Calandra G. Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation. Biol Blood Marrow Transplant 2010;16:695-700
   PubMed Web of Science ®Google Scholar
• Liles WC, Rodger E, Broxmeyer HE, Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005;45:295-300
   PubMed Web of Science ®Google Scholar
• Gazitt Y, Freytes CO, Akay C, Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients. Stem Cells Dev 2007;16:657-66
   PubMed Web of Science ®Google Scholar
• Genzyme. Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. ClinicalTrials.gov NCT00694590. Available from: http://clinicaltrials.gov/ct2/show/NCT00694590?term=NCT00694590&rank=1
   Google Scholar
• Duke University, Celgene Corp., Genzyme. Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL) ClinicalTrials.gov NCT01373229. Available from: http://clinicaltrials.gov/ct2/show/NCT01373229?term=NCT01373229&rank=1
   Google Scholar
• Ichiyama K, Yokoyama-Kumakura S, Tanaka Y, A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 2003;100:4185-90
   PubMed Web of Science ®Google Scholar
• Murakami T, Kumakura S, Yamazaki T, The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100. Antimicrob Agents Chemother 2009;53:2940-8
   PubMed Web of Science ®Google Scholar
• Beider K, Begin M, Abraham M, CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp Hematol 2011;39:282-92
   PubMed Web of Science ®Google Scholar
• Biokine Therapeutics Ltd. Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients. ClinicalTrials.gov NCT01010880. Available from: http://clinicaltrials.gov/ct2/show/NCT01010880?term=NCT01010880&rank=1
   Google Scholar
• Liu Q, Chen T, Chen G, Triptolide impairs dendritic cell migration by inhibiting CCR7 and COX-2 expression through PI3-K/Akt and NF-kappaB pathways. Mol Immunol 2007;44:2686-96
   PubMed Web of Science ®Google Scholar
• Villablanca EJ, Zhou D, Valentinis B, Selected natural and synthetic retinoids impair CCR7- and CXCR4-dependent cell migration in vitro and in vivo. J Leukoc Biol 2008;84:871-9
   PubMed Web of Science ®Google Scholar
• Satoh K, Fukumoto Y, Nakano M, Statin ameliorates hypoxia-induced pulmonary hypertension associated with down-regulated stromal cell-derived factor-1. Cardiovasc Res 2009;81:226-34
   PubMed Web of Science ®Google Scholar
• Grip O, Janciauskiene S. Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease. PLoS One 2009;4:e5263
   Google Scholar
• Yilmaz A, Reiss C, Tantawi O, HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis 2004;172:85-93
   PubMed Web of Science ®Google Scholar
• Damas JK, Boullier A, Waehre T, Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy. Arterioscler Thromb Vasc Biol 2005;25:2567-72
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V, Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 2002;99:4079-86
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Kang J, Capone L, Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010;10:155-67
   PubMed Web of Science ®Google Scholar
• LeBlanc R, Hideshima T, Catley LP, Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004;103:1787-90
   PubMed Web of Science ®Google Scholar
• Huang MC, Greig NH, Luo W, Preferential enhancement of older human T cell cytokine generation, chemotaxis, proliferation and survival by lenalidomide. Clin Immunol 2011;138:201-11
   PubMed Web of Science ®Google Scholar
• Xu Y, Li J, Ferguson GD, Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases. Blood 2009;114:338-45
   PubMed Web of Science ®Google Scholar
• Oliveira AM, Maria DA, Metzger M, Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients. Leuk Res 2009;33:970-3
   PubMed Web of Science ®Google Scholar
• Lee ES, Kim YA, Kwon HJ, Thalidomide upregulates macrophage inflammatory protein-1alpha in a herpes simplex virus-induced Behcet's disease-like animal model. Arch Dermatol Res 2004;296:175-81
   PubMed Web of Science ®Google Scholar
• Fuchida SI, Shimazaki C, Hirai H, The effects of thalidomide on chemotactic migration of multiple myeloma cell lines. Int J Lab Hematol 2008;30:220-9
   PubMed Web of Science ®Google Scholar
• Braunstein I, Goodman NG, Rosenbach M, Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare. J Am Acad Dermatol 2011; published online 6 August 2011; doi:S0190-9622(11)00124-1 [pii];10.1016/j.jaad.2011.01.015
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Larson S, Trinkaus K, A phase II multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011;118:5119-25
   PubMed Web of Science ®Google Scholar
• Schall TJ, Proudfoot AE. Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nat Rev Immunol 2011;11:355-63
   PubMed Web of Science ®Google Scholar
• Washington University School of Medicine. AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia. ClinicalTrials.gov NCT00512252. Available from: http://clinicaltrials.gov/ct2/show/NCT00512252?term=NCT00512252&rank=1
   Google Scholar
• Washington University School of Medicine. Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia. ClinicalTrials.gov NCT00906945. Available from: http://clinicaltrials.gov/ct2/show/NCT00906945?term=NCT00906945&rank=1
   Google Scholar
• M.D. Anderson Cancer Center, Bayer, Genzyme, Onyx Pharmaceuticals. Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations ClinicalTrials.gov NCT00943943. Available from: http://clinicaltrials.gov/ct2/show/NCT00943943?term=NCT00943943&rank=1
   Google Scholar
• Genzyme. Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia. ClinicalTrials.gov NCT00990054. Available from: http://clinicaltrials.gov/ct2/show/NCT00990054?term=NCT00990054&rank=1
   Google Scholar
• Washington University School of Medicine. IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML). ClinicalTrials.gov NCT01027923. Available from: http://clinicaltrials.gov/ct2/show/NCT01027923?term=NCT01027923&rank=1
   Google Scholar
• St. Jude Children's Research Hospital, Genzyme. A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation. ClinicalTrials.gov NCT01068301. Available from: http://clinicaltrials.gov/ct2/show/NCT01068301?term=NCT01068301&rank=1
   Google Scholar
• M.D. Anderson Cancer Center, Genzyme. Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML). ClinicalTrials.gov NCT01160354. Available from: http://clinicaltrials.gov/ct2/show/NCT01160354?term=NCT01160354&rank=1
   Google Scholar
• Cardiff University, Leukaemia & Lymphoma Research Group, Experimental Cancer Medicine Centre Network. A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220 or the CXCR4 Inhibitor Plerixafor With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. ClinicalTrials.gov NCT01236144. Available from: http://clinicaltrials.gov/ct2/show/NCT01236144?term=NCT01236144&rank=1
   Google Scholar
• Emory University, Children's Healthcare of Atlanta, Pediatric Oncology Experimental Therapeutics Investigation Consortium POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients. ClinicalTrials.gov NCT01319864. Available from: http://clinicaltrials.gov/ct2/show/NCT01319864?term=NCT01319864&rank=1
   Google Scholar
• Weill Medical College of Cornell University, Genzyme. Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML). ClinicalTrials.gov NCT01352650. Available from: http://clinicaltrials.gov/ct2/show/NCT01352650?term=NCT01352650&rank=1
   Google Scholar
• Kyowa Hakko Kirin Co., Ltd. Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma. ClinicalTrials.gov NCT00920790. Available from: http://clinicaltrials.gov/ct2/show/NCT00920790?term=NCT00920790&rank=1
   Google Scholar
• Kyowa Hakko Kirin Co., Ltd. Study of KW-0761 in Subjects With CCR4-positive Peripheral T/NK-cell Lymphoma. ClinicalTrials.gov NCT01192984. Available from: http://clinicaltrials.gov/ct2/show/NCT01192984?term=NCT01192984&rank=1
   Google Scholar
• Kyowa Hakko Kirin Co., Ltd. Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL. ClinicalTrials.gov NCT00355472. Available from: http://clinicaltrials.gov/ct2/show/NCT00355472?term=NCT00355472&rank=1
   Google Scholar
• Kyowa Hakko Kirin Co., Ltd. Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15. ClinicalTrials.gov NCT01173887. Available from: http://clinicaltrials.gov/ct2/show/NCT01173887?term=NCT01173887&rank=1
   Google Scholar
• Kyowa Hakko Kirin Pharma, Inc. Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001. ClinicalTrials.gov NCT01226472. Available from: http://clinicaltrials.gov/ct2/show/NCT01226472?term=NCT01226472&rank=1
   Google Scholar